{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:38:43Z","timestamp":1765355923902},"reference-count":20,"publisher":"Japan Society for Clinical Immunology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2177\/jsci.38.109","type":"journal-article","created":{"date-parts":[[2015,5,25]],"date-time":"2015-05-25T22:07:00Z","timestamp":1432591620000},"page":"109-115","source":"Crossref","is-referenced-by-count":7,"title":["Risk of serious infection in patients with rheumatoid arthritis"],"prefix":"10.2177","volume":"38","author":[{"given":"Atsushi","family":"HASHIMOTO","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Sagamihara National Hospital, National Hospital Organization"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"MATSUI","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sagamihara National Hospital, National Hospital Organization"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Dixon, W.G., et al.: Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. <i>Arthritis Rheum<\/i>. <b>56<\/b>: 2896-2904, 2007."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Baum, J.: Infection in rheumatoid arthritis. <i>Arthritis Rheum<\/i>. <b>14<\/b>: 135-137, 1971.","DOI":"10.1002\/art.1780140119"},{"key":"3","unstructured":"3) Doran, M.F., et al.: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. <i>Arthritis Rheum<\/i>. <b>46<\/b>: 2287-2293, 2002."},{"key":"4","unstructured":"4) Doran, M.F., et al.: Predictors of infection in rheumatoid arthritis. <i>Arthritis Rheum<\/i>. <b>46<\/b>: 2294-2300, 2002."},{"key":"5","unstructured":"5) Smitten, A.L., et al.: The risk of hospitalized infection in patients with rheumatoid arthritis. <i>J Rheumatol<\/i>. <b>35<\/b>: 387-393, 2008."},{"key":"6","unstructured":"6) Au, K., et al.: High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. <i>Ann Rheum Dis<\/i>. <b>70<\/b>: 785-791, 2011."},{"key":"7","unstructured":"7) Komano, Y., et al.: Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. <i>J Rheumatol<\/i>. <b>38<\/b>: 1258-1264, 2011."},{"key":"8","unstructured":"8) Listing, J., et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. <i>Arthritis Rheum<\/i>. <b>52<\/b>: 3403-3412, 2005."},{"key":"9","unstructured":"9) Bongartz, T., et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. <i>JAMA<\/i>. <b>295<\/b>: 2275-2285, 2006."},{"key":"10","unstructured":"10) Leombruno, J.P., et al.: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. <i>Ann Rheum Dis<\/i>. <b>68<\/b>: 1136-1145, 2009."},{"key":"11","unstructured":"11) Michaud, T.L., et al.: The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials. <i>Am J Med<\/i>. <b>127<\/b>: 1208-1232, 2014."},{"key":"12","unstructured":"12) Salliot, C., et al.: Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. <i>Ann Rheum Dis<\/i>. <b>68<\/b>: 25-32, 2009."},{"key":"13","unstructured":"13) Campbell, L., et al.: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. <i>Rheumatology (Oxford)<\/i>. <b>50<\/b>: 552-562, 2011."},{"key":"14","unstructured":"14) Alonso-Ruiz, A., et al.: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. <i>BMC Musculoskelet Disord<\/i>. <b>9<\/b>: 52, 2008."},{"key":"15","unstructured":"15) Wiens, A., et al.: Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. <i>Pharmacotherapy<\/i>. <b>30<\/b>: 339-353, 2010."},{"key":"16","unstructured":"16) Thompson, A.E., et al.: Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. <i>Arthritis Rheum<\/i>. <b>63<\/b>: 1479-1485, 2011."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Singh, J.A., et al.: Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>Cochrane Database Syst Rev<\/i>. CD008794, 2011.","DOI":"10.1002\/14651858.CD008794"},{"key":"18","unstructured":"18) Aaltonen, K.J., et al.: Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. <i>PLoS One<\/i>. <b>7<\/b>: e30275, 2012."},{"key":"19","unstructured":"19) Sakai, R., et al.: The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg\/week in patients with rheumatoid arthritis. <i>Mod Rheumatol<\/i>. <b>21<\/b>: 444-448, 2011."},{"key":"20","unstructured":"20) Wolfe, F., et al.: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. <i>Arthritis Rheum<\/i>. <b>54<\/b>: 628-634, 2006."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1\u60a3\u8005\u306b\u304a\u3051\u308b\u91cd\u75c7\u611f\u67d3\u75c7\u30ea\u30b9\u30af\u56e0\u5b50\u306e\u691c\u8a0e"],"language":"en","deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T04:43:56Z","timestamp":1652071436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/38\/2\/38_109\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.38.109","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}